© COPYRIGHT 2023 IMAGEN THERAPEUTICS LTD.
Company Registered in England & Wales No. 06373341
Patient-derived cell (PDC) models bridge the gap between conventional cancer lines that do not faithfully replicate clinical responses and costly and time-consuming patient-derived xenograft (PDX) models. To enable large scale drug sensitivity testing in PDCs, we have developed a phenotypic High Content Imaging (HCI) platform with a multitude of endpoint readouts. These can be applied to assess biomarkers of response, potential combination therapy synergies and the modelling of clinical trial participants.
© COPYRIGHT 2023 IMAGEN THERAPEUTICS LTD.
Company Registered in England & Wales No. 06373341